The Association for Accessible Medicines and its Biosimilars Council have urged the US Federal Trade Commission to investigate the business practices of pharmacy benefit managers, specifically their competitive impact and “various abusive behaviors that undermine patient access to safe, affordable pharmaceutical care.”
The organization called for the FTC to do this in a comment letter responding to a request for information...